Exelixis Reaffirms Dual-Franchise Strategy as Cabozantinib Surpasses $3B, but Valuation Limits Upside

What happened

Exelixis CEO Michael Morrissey stated the company is focused on expanding its oncology franchises through internal development, selective business development, and collaborations while preparing for the planned launch of zanzalintinib in metastatic colorectal cancer, and noting cabozantinib has generated over $3 billion in cumulative revenue. The DeepValue master report rates EXEL a WAIT, arguing the stock at ~$44 trades at ~17x EPS with much of the near-term upside already reflected and with structural risks including the 2026 composition-of-matter patent expiry, pricing pressure, and binary zanzalintinib regulatory outcomes. The news aligns with the report's acknowledgment of zanzalintinib as the next growth engine but does not de-risk its approval or commercial uptake, while the company remains overwhelmingly dependent on Cabometyx cash flows. The report flags crowded positioning and recent institutional selling, suggesting the market may already be pricing in future success. Overall, the event reinforces management's stated strategy but does not change the fundamental risk-reward, favoring patience over chasing the stock at current levels.

Implication

Investors should avoid buying after this news, as the market has likely priced in Cabometyx strength and zanzalintinib optionality, and the WAIT rating calls for a pullback to the high-$30s or clear evidence of above-guidance Cabometyx performance and smooth FDA progress for zanzalintinib. The announced focus on business development could yield deals that diversify revenue, but execution and timing are uncertain and not yet reflected in valuation. Key monitorables include quarterly TRx share in RCC/NET, zanzalintinib NDA acceptance and PDUFA date, and cabozantinib net pricing under policy pressure. A decline toward $38 would improve the risk-reward, while sustained Cabometyx outperformance and positive regulatory milestones could justify an upgrade within 6-12 months. Position sizing should remain modest given single-product concentration and the approaching patent cliff.

Thesis delta

The investment thesis remains unchanged: EXEL is a profitable but single-product-dependent oncology company trading at a reasonable valuation with limited margin of safety. The CEO's comments on business development and zanzalintinib launch are consistent with prior disclosures and do not introduce new information that would alter the WAIT rating. Potential collaboration deals add optionality but are too early to incorporate into intrinsic value.